## SPECIFICATION

Please amend the specification as follows:

Please replace paragraph [0067] with the following paragraph:

[0067] A sample of 15 mg F5000 PEG-insulin microspheres (14.1% drug content, PLGA 45:55, 0.15 dl/g IV, acid end groups) was suspended in 1.5 ml phosphate buffered saline (pH 7.4, 0.02% sodium azide and 0.02% TWEEN-20<sup>TM</sup>) and incubated at 37° C. The supernatant was withdrawn at intervals and analyzed by RP HPLC for released PEG-insulin. The buffer was replaced with fresh PBS and the incubation continued. The data were analyzed for cumulative release as a function of incubation time (FIG. 4). Less than 1.0% of the PEG\_insulin is released in the first day and over 95% is released within 18 days. The low "burst" release, high total release and duration over approximately a two-week period are highly desired features of a sustained release insulin formulation.

Please replace the title on page 1 with the following title:

Materials and Methods for Preparing Protein-Polymer Conjugates

Please replace paragraph [0001] of the specification with the following paragraph:

This application is a 371 of PCT/US04/10995 and claims priority to U.S. Provisional Application No. 60/224,499 entitled, "Methods and Compositions for Enhanced Delivery of Bioactive Molecules" filed on October 31, 2000, the contents of which are incorporated herein by reference.

Serial No. 10/553,570

Page 6 of 10

Attorney Docket No. 007184-51 US